Rare and Coding Region Genetic Variants Associated With Risk of Ischemic Stroke: The NHLBI Exome Sequence Project by Auer, Paul L. et al.
Rare and Coding Region Genetic Variants Associated With Risk 
of Ischemic Stroke:
The NHLBI Exome Sequence Project
Paul L. Auer, PhD, Mike Nalls, PhD, James F. Meschia, MD, Bradford B. Worrall, MD, W. T. 
Longstreth Jr, MD, Sudha Seshadri, MD, Charles Kooperberg, PhD, Kathleen M. Burger, 
DO, Christopher S. Carlson, PhD, Cara L. Carty, PhD, Wei-Min Chen, PhD, L. Adrienne 
Cupples, PhD, Anita L. DeStefano, PhD, Myriam Fornage, PhD, John Hardy, PhD, Li Hsu, 
PhD, Rebecca D. Jackson, MD, Gail P. Jarvik, MD, PhD, Daniel S. Kim, BS, Kamakshi 
Lakshminarayan, MD, Leslie A. Lange, PhD, Ani Manichaikul, PhD, Aaron R. Quinlan, PhD, 
Andrew B. Singleton, PhD, Timothy A. Thornton, PhD, Deborah A. Nickerson, PhD, Ulrike 
Peters, PhD, Stephen S. Rich, PhD, and The National Heart Lung, and Blood Institute 
Exome Sequencing Project
Joseph J. Zilber School of Public Health, University of Wisconsin, Milwaukee (Auer); Division of 
Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington (Auer, 
Kooperberg, Carlson, Carty, Hsu, Peters); Laboratory of Neurogenetics, National Institute on 
Aging, National Institutes of Health, Bethesda, Maryland (Nalls, Singleton); Department of 
Neurology, Mayo Clinic, Jacksonville, Florida (Meschia); Department of Neurology, University of 
Virginia, Charlottesville (Worrall); Department of Neurology, University of Washington, Seattle 
(Longstreth); Department of Neurology, Boston University School of Medicine, Boston, 
Massachusetts (Seshadri); Department of Neurology, George Washington University Hospital, 
Washington, DC (Burger); Center for Public Health Genomics, University of Virginia, 
Charlottesville (Chen, Manichaikul, Quinlan, Rich); Department of Biostatistics, Boston University 
School of Public Health, Boston, Massachusetts (Cupples, DeStefano); Institute for Molecular 
Medicine, University of Texas Health Science Center, Houston (Fornage); Department of 
Neuroscience, Reta Lila Weston Institute, University College London, London, England (Hardy); 
Corresponding Author: Stephen S. Rich, PhD, Center for Public Health Genomics, University of Virginia, 3232 West Complex, PO 
Box 800717, Charlottesville, VA 22908 (ssr4n@virginia.edu).. 
Author Contributions: Drs Peters and Rich contributed equally to the manuscript. Dr Rich had full access to all the data in the study 
and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Kooperberg, Peters, Rich.
Acquisition, analysis, or interpretation of data: Auer, Nalls, Meschia, Worrall, Longstreth, Seshadri, Burger, Carlson, Carty, Chen, 
Cupples, DeStefano, Fornage, Hardy, Hsu, Jackson Jarvik, Kim, Lakshminarayan, Lange, Manichaikul, Quinlan, Singleton, Thornton, 
Nickerson, Rich.
Drafting of the manuscript: Rich.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Auer, Nalls, Kooperberg.
Obtained funding: Jackson, Nickerson, Rich.
Administrative, technical, or material support: Kooperberg, Nickerson, Peters Rich.
Study supervision: Nickerson, Peters, Rich.
Conflict of Interest Disclosures: None reported.
Group Information: NHLBI Exome Sequencing Project members are listed in eAppendix 1 in the Supplement.
Additional Contributions: The support of the research institutions, study investigators, field staff, and study participants assisted in 
creating this resource for biomedical research.
HHS Public Access
Author manuscript
JAMA Neurol. Author manuscript; available in PMC 2015 December 09.
Published in final edited form as:













Department of Internal Medicine, The Ohio State University, Columbus (Jackson); Department of 
Medicine, University of Washington, Seattle (Jarvik); Department of Genome Sciences, University 
of Washington, Seattle (Kim, Nickerson); Department of Neurology, University of Minnesota, 
Minneapolis (Lakshminarayan); Department of Genetics, University of North Carolina, Chapel Hill 
(Lange); Department of Biostatistics, University of Washington, Seattle (Thornton)
Abstract
IMPORTANCE—Stroke is the second leading cause of death and the third leading cause of years 
of life lost. Genetic factors contribute to stroke prevalence, and candidate gene and genome-wide 
association studies (GWAS) have identified variants associated with ischemic stroke risk. These 
variants often have small effects without obvious biological significance. Exome sequencing may 
discover predicted protein-altering variants with a potentially large effect on ischemic stroke risk.
OBJECTIVE—To investigate the contribution of rare and common genetic variants to ischemic 
stroke risk by targeting the protein-coding regions of the human genome.
DESIGN, SETTING, AND PARTICIPANTS—The National Heart, Lung, and Blood Institute 
(NHLBI) Exome Sequencing Project (ESP) analyzed approximately 6000 participants from 
numerous cohorts of European and African ancestry. For discovery, 365 cases of ischemic stroke 
(small-vessel and large-vessel subtypes) and 809 European ancestry controls were sequenced; for 
replication, 47 affected sibpairs concordant for stroke subtype and an African American case-
control series were sequenced, with 1672 cases and 4509 European ancestry controls genotyped. 
The ESP's exome sequencing and genotyping started on January 1, 2010, and continued through 
June 30, 2012. Analyses were conducted on the full data set between July 12, 2012, and July 13, 
2013.
MAIN OUTCOMES AND MEASURES—Discovery of new variants or genes contributing to 
ischemic stroke risk and subtype (primary analysis) and determination of support for protein-
coding variants contributing to risk in previously published candidate genes (secondary analysis).
RESULTS—We identified 2 novel genes associated with an increased risk of ischemic stroke: a 
protein-coding variant in PDE4DIP (rs1778155; odds ratio, 2.15; P = 2.63 × 10−8) with an 
intracellular signal transduction mechanism and in ACOT4 (rs35724886; odds ratio, 2.04; P = 1.24 
× 10−7) with a fatty acid metabolism; confirmation of PDE4DIP was observed in affected sibpair 
families with large-vessel stroke subtype and in African Americans. Replication of protein-coding 
variants in candidate genes was observed for 2 previously reported GWAS associations: ZFHX3 
(cardioembolic stroke) and ABCA1 (large-vessel stroke).
CONCLUSIONS AND RELEVANCE—Exome sequencing discovered 2 novel genes and 
mechanisms, PDE4DIP and ACOT4, associated with increased risk for ischemic stroke. In 
addition, ZFHX3 and ABCA1 were discovered to have protein-coding variants associated with 
ischemic stroke. These results suggest that genetic variation in novel pathways contributes to 
ischemic stroke risk and serves as a target for prediction, prevention, and therapy.
According to the 2010 Global Burden of Disease study, stroke is the second leading cause of 
death and the third leading cause of years of life lost.1,2 Ischemic stroke is the overt 
symptomatic manifestation of brain infarction, but the burden of cerebrovascular disease is 
much greater, with many more covert infarctions not resulting in the diagnosis of clinical 
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stroke. More than 7% of asymptomatic adults in the general population have radiographic 
evidence of brain infarction,3 with substantially higher rates in the elderly population.4 
Although many effective treatments for stroke exist, novel strategies for stroke prediction, 
prevention, and therapy need to be found.
Epidemiologic and family studies5,6 support an inherited component to stroke risk. Family-
based linkage studies, including Cerebral Autosomal Dominant Arteriopathy With Sub-
cortical Infarcts and Leukoencephalopathy and Cerebral Autosomal Recessive Arteriopathy 
With Subcortical Infarcts and Leukoencephalopathy,7 identified rare forms of stroke. 
Ischemic stroke studies include large candidate gene association meta-analyses,8,9 
mendelian randomization,10 studies of affected sibpair families,11 and genome-wide 
association studies (GWAS).12–14 The joint International Stroke Genetics Consortium/
Wellcome Trust Case Control Consortium 2 (WTCCC2) effort14 identified HDAC9 (7p21.1; 
GenBank NM_058176) and confirmed associations of ischemic stroke with variants in 
PITX2 (GenBank KJ891816) and ZFHX3 (GenBank NM_006885) (cardioembolic stroke) 
and in 9p21 (large-vessel/atherosclerotic stroke). The Australian Stroke Genetics 
Collaborative, the WTCCC2, and the International Stroke Genetics Consortium have 
identified and replicated the chromosome 6p21.1 large-artery susceptibility locus.13 
Discovering the missing heritability for ischemic stroke could provide critical insights into 
the cause of the disease, novel pathways, and therapeutic targets.15
Rare, protein-coding variation could contribute a burden of risk for ischemic stroke, 
attributable to multiple variants in a gene rather than any individual variant.16,17 Exome 
sequencing in ischemic stroke has been performed only as a pilot study.18 Herein, we 
present results from what we believe to be the first large-scale study of protein-coding 
region variants in ischemic stroke from the National Heart, Lung, and Blood Institute 
(NHLBI) Exome Sequencing Project (ESP). We describe analyses used to identify novel 
stroke susceptibility genes, determine genes and variants that are specific to stroke subtypes, 
and establish replication of previous GWAS and candidate gene associations.
Methods
Participating Studies and Design
The NHLBI ESP ascertained samples of European American and African American 
ancestry. Data were obtained on NHLBI cohorts (Atherosclerosis Risk in Communities, 
Coronary Artery Risk Development in Young Adults, Cardiovascular Health Study, 
Framingham Heart Study, Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, 
and the Women's Health Initiative [WHI]) and 2 National Institute of Neurological 
Disorders and Stroke studies (Siblings With Ischemic Stroke Study [SWISS] and Ischemic 
Stroke Genetic Study [ISGS)]). Characteristics of the participants analyzed are presented in 
Table 1.
Discovery analysis by exome sequencing focused on small-vessel and large-vessel subtypes 
in unrelated persons of European ancestry. Replication was conducted in small- and large-
vessel subtypes in SWISS and ESP African American individuals, as well as ExomeChip 
data from European American participants in the WHI that included cardioembolic sub-
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types. Exome sequencing was performed on 365 unrelated cases (327 cases from NHLBI 
cohorts and 38 cases from ISGS: 114 with large-vessel subtype, 249 with small-vessel 
subtype, and 2 undetermined), 47 affected sibpairs from SWISS (94 individuals, used in 
replication: 28 pairs concordant for small-vessel subtype and 19 pairs concordant for large-
vessel sub-type), and African Americans (83 cases and 317 controls, used in replication). 
ExomeChip genotyping was performed on 1672 unrelated WHI ischemic stroke cases: 107 
with large-vessel sub-type, 224 with small-vessel subtype, 605 with cardioembolic subtype, 
and 736 of undetermined subtype. Cases classified as undetermined were included in the 
overall case-control analysis but not the subtype-specific analyses. Controls (n = 809) were 
identified as participants with exome sequence data who had not experienced a stroke or 
myocardial infarction at baseline or on subsequent follow-up and as individuals who were 
originally ascertained on the basis of low blood pressure or decreased low-density 
lipoprotein cholesterol levels. Controls for ExomeChip analysis were 4509 WHI participants 
who self-reported having no history of stroke and myocardial infarction and no family 
history of stroke.
Ischemic Stroke Classification
Ischemic stroke was defined as a typical clinical syndrome with radiologic confirmation of 
brain infarction or the absence of an alternative diagnosis for the clinical syndrome. Stroke 
subtyping was based on the Trial of Org 10172 in Acute Stroke Treatment classification 
system.19 Brain imaging by computed tomographic scanning, magnetic resonance imaging, 
or autopsy confirmation was available to classify all cases. Relevant institutional review 
boards approved participating studies, and all participants provided written informed consent 
for participating in the original study as well as for genetic research. There was no financial 
compensation for use of existing data and samples from the contributing cohorts as part of 
this study.
Genetic Data
Exome sequencing was performed at the Broad Institute and the University of Washington 
(eAppendix 2 in the Supplement). ExomeChip genotyping was performed at the Broad 
Institute (eAppendix 3 in the Supplement). The ESP exome sequencing and ExomeChip 
genotyping started on January 1, 2010, and continued through June 30, 2012. Analyses were 
conducted on the full data set between July 12, 2012, and July 13, 2013. A total of 225 239 
protein-coding variants were common to both ESP exome sequencing and ExomeChip geno-
typing, of which 119 963 were polymorphic in the full ESP sample (n = 7355). The self-
reported ancestry and genetic ancestry distributions by principal components analysis are 
shown in eFigure 1 in the Supplement.
Statistical Analysis
Single-variant tests and 2 gene-based tests were used to determine the association with 
ischemic stroke, conditional on the minor allele frequency (MAF) of individual variants 
(eAppendix 4 in the Supplement). Variants with MAF of 0.5% or more and at least 100 
observations with a nonmissing genotype were analyzed using a single-variant test. For 
gene-based tests, only missense, splice, or nonsense variants were considered. Variants with 
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MAF of 5% or less were analyzed with the sequence kernel association test (SKAT),20 or 
variants with MAF of 1% or less analyzed with the combined multivariate and collapsing 
method, using variants with MAF of less than 1% (CMC/T1 test).21 For SKAT and 
CMC/T1, only genes with cumulative MAF of 0.5% or more were assessed. Analyses were 
conducted separately for exome sequence (combining data from all cohorts and ISGS) and 
ExomeChip (WHI) data; a meta-analysis was conducted using seqMeta software (http://
cran.r-project.org/web/packages/seqMeta/).22 Covariate adjustment included participant's 
age at baseline and sex, as appropriate. For autosomal variants, a log-additive genetic model 
was used; for sex chromosome variants, a dominance model was used.
Ischemic stroke and subtype analyses used 2037 cases and 5318 controls with ESP exome 
sequencing or ExomeChip data. Association of ischemic stroke with any single variant used 
P < 4.17 × 10−7 (0.05/119 963) as the threshold for exomewide significance. Restriction to 
variants with MAF of 0.005 or more and at least 100 observations with a nonmissing 
genotype yielded 25 467 variants, with a significance threshold at P < 1.96 × 10−6. Gene-
level associations used a variety of statistical tests and MAF cutoffs23; CMC/T1 is most 
powerful when all variants in a gene influence risk in the same direction; SKAT is more 
powerful when the variants in a gene influence risk in opposite directions. For CMC/T1, 
genes were included for individual variants with MAF of 0.01 or less and cumulative MAF 
of 0.005 or more, resulting in 6173 informative genes with a threshold of P < 8.10 × 10−6. 
For SKAT, there were 8361 genes with MAF of 0.05 or less and cumulative MAF of 0.005 
or more, with a threshold of P < 5.98 × 10−6. In the discovery phase, these analyses were 
conducted for all ischemic stroke, small-vessel subtype, and large-vessel subtype. Affected 
sibpairs from SWISS were analyzed using identity-by-descent methods (eAppendix 4 in the 
Supplement). Regions of excess identity by descent were examined, focusing on missense, 
nonsense, stop-gain/loss functional variants. Single-variant and aggregate identity-by-
descent probabilities of each gene across all available sibpairs were calculated to generate 
logarithm-of-the-odds scores for excess identity-by-descent sharing, adjusting for local 
recombination rates based on European ancestry estimates (HapMap phase 3), repeated for 
sibpairs concordant for small-vessel and large-vessel subtypes. The distribution of scores 
from the identity-by-descent analyses is shown in eFigure 2 in the Supplement.
Targeted secondary analysis of 59 candidate genes previously associated with ischemic 
stroke, stroke risk factors, and mendelian syndromes yielded 134 variants. Most of these 
variants are not located in protein-coding regions; however, proxies were identified with 
strong linkage disequilibrium with ESP-defined protein-coding variants. For single-variant 
tests, significance was defined as P < 1.86 × 10−4. For gene-based tests, 33 genes contained 
polymorphic variants for analysis and significance was defined as P < 7.58 × 10−4 since 2 
gene-based tests (CMC/T1 and SKAT) were used.
Results
Exome Variants Associated With Ischemic Stroke
Single-variant tests identified 2 protein-coding variants significantly associated with 
ischemic stroke (Table 2). A common (MAF, 0.316) missense variant, rs1778155, in 
PDE4DIP (phosphodiesterase 4D-interacting protein; 1q21.1; GenBank NM_014644) was 
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associated with ischemic stroke (odds ratio [OR], 2.15; P = 2.63 × 10−8). An infrequent 
(MAF, 0.017) missense variant, rs35724886, in ACOT4 (acyl-coenzyme A thioesterase 4; 
14q24.3; GenBank NM_152331) was associated with ischemic stroke (OR, 2.04; P = 1.2 × 
10−7). Although not reaching exomewide significance, a common (MAF, 0.379) variant, 
rs5001076, in PRIM2 (primase, DNA, polypeptide 2 [58 kilodaltons (kDa)]); 6p11.2; 
GenBank NM_000947) showed evidence of increased risk with ischemic stroke (OR, 2.11; 
P = 2.96 × 10−6) (Table 2).
Rare and infrequent protein-coding variants in PDE4DIP from exome sequencing in 365 
cases and 809 controls and their estimated effect on ischemic stroke risk are shown in the 
Figure. A large complex gene (240.030 kilobases [kb]; 2346 amino acids, 265 kDa), 
PDE4DIP has 86 distinct introns, 64 different messenger RNAs, 49 alternatively spliced 
variants, and at least 10 transcription factor binding sites in its promoter. In contrast, ACOT4 
is a small gene (4.791 kb; 421 amino acids, 46 kDa) with 2 distinct introns and 1 spliced 
messenger RNA. Both genes are expressed in the brain and in other tissues.
The results of no single-variant or gene-based test attained statistical significance for the 
small-vessel (lacunar) stroke subtype (Table 3). PDE4DIP rs1778155 had direction and size 
of effect on risk consistent in the all-stroke and small-vessel stroke categories (OR, 2.03; 
meta-analysis P = 7.96 × 10−6). ACOT4 rs35724886 also had the same direction and similar 
size of effect on risk (OR, 1.95; meta-analysis P = 2.43 × 10−5). One novel gene, CEP164 
(centrosomal protein 164 kDa; 11q23.3; GenBank NM_014956) with 24 rare variants 
(cumulative MAF, 0.01) approached statistical significance (SKAT meta-analysis P = 7.93 × 
10−6).
Within large-vessel (atherosclerotic) stroke, no single-variant or gene-based test attained 
statistical significance (Table 4). PDE4DIP rs1778155 had a strong effect and consistent 
direction (OR, 2.40; P = 2.18 × 10−5). Single-variant tests did not support ACOT4 
rs35724886, but gene-based tests of many infrequent or rare variants provided suggestive 
evidence for association (eg, SPSB3 [GenBank KJ899913], SLC22A5 [GenBank KJ897580], 
PGAP1 [GenBank NM_024989], KIF21A [GenBank NM_001173464], and MX1 [GenBank 
NM_001144925]) with large-vessel subtype.
Cases of cardioembolic ischemic stroke were not selected for ESP exome sequencing; these 
participants were sequenced only if they were selected for other (nonstroke) phenotypes or 
were included later for ExomeChip genotyping. No statistically significant associations with 
cardioembolic stroke were found by either single-variant or gene-based tests. The most 
significant single-variant association was with PPIP5K2 rs35671301 (GenBank 
NM_001276277) (diphosphoinositol pentakisphosphate kinase 2; 5q21.1; OR, 3.59; MAF, 
0.011; meta-analysis P = 1.01 × 10−5). The SKAT test also provided support for PPIP5K2 
on risk in the cardioembolic stroke (5 variants with cumulative MAF, 0.104; meta-analysis P 
= 1.51 × 10−5).
Replication of Exome Variants Associated With Ischemic Stroke
Single-nucleotide polymorphisms in PDE4DIP and ACOT4 were analyzed in an 
independent set of affected sibpairs from SWISS and unrelated ESP African American 
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participants. The PDE4DIP rs1778155 variant had significantly increased allele sharing 
identity by descent (P = 1.16 × 10−4) and was observed in 16 of 19 large-vessel concordant 
pairs with a logarithm of the odds of 6.07 (OR, 2.41; MAF, 0.302; P = 2.18 × 10−5) and a 
false discovery rate of P = 6.39 × 10−3. ACOT4 rs35724886 was not polymorphic in either 
the SWISS or WHI ExomeChip data. A significant association with ischemic stroke was 
observed for PDE4DIP rs1778155 in the ESP African American samples (MAF, 0.191; OR, 
2.34, P = 7.50 × 10−4). This variant failed genotype quality control metrics on the 
ExomeChip and was not analyzed. In African Americans, no significant association was 
detected for ACOT4 rs35724886 with ischemic stroke although the effect size was similar 
(OR, 1.86; MAF, 0.180; P = .31).
Analysis of Previously Identified Candidate Genes and Variants
We identified 59 published candidate genes to be analyzed with the single-variant and gene-
based tests. A single variant in ABCA1 (adenosine triphosphate-binding cassette, subfamily 
A [ABC1], member 1; 9q31.1; GenBank NM_005502) was associated with all ischemic 
stroke (meta-analysis P = 1.94 × 10−4) and in both subtypes (small-vessel meta-analysis P 
= .008; large-vessel meta-analysis P = .02). Variants in ZFHX3 (zinc finger homeobox 3; 
16q22.3), a candidate gene for atrial fibrillation, were nominally associated with all ischemic 
stroke using the CMC/T1 test (P = .001), primarily in the cardioembolic subtype (P = .04). 
Results for all candidate genes are presented in eTables 1 through 4 in the Supplement.
Discussion
We report the results of ESP exome sequencing and ExomeChip genotyping of 2037 cases 
of ischemic stroke and 5318 controls, with replication in an African American population 
and a collection of affected sibpairs. We present evidence supporting the role of protein-
coding variants in 2 novel genes, PDE4IP and ACOT4, which are associated with an 
increased risk of ischemic stroke. We evaluated protein-coding variants in previously 
reported genes associated with ischemic stroke, and support the role of ABCA1 in large-
vessel stroke and ZFHX3 in cardioembolic stroke.
A primary interacting partner of PDE4DIP is PDE4D (phosphodiesterase 4D, cAMP-
specific; GenBank NM_001104631), originally identified as linked to ischemic stroke in 
Icelandic families.24 The PDE4D variants have been extensively studied25–28 for association 
with ischemic stroke risk in diverse populations, with equivocal results. A meta-analysis29 
of ischemic stroke was conducted on 7 studies, using approximately 12 000 cases and 15 
000 controls that included 6 single-nucleotide polymorphisms in PDE4D. In the meta-
analysis, PDE4D rs702553 had a significant association with ischemic stroke. The PDE4D 
result, coupled with PDE4DIP identified in the present study,30,31 supports a role of this 
pathway in ischemic stroke.
The ACOT4 gene encodes an enzyme that catalyzes the hydrolysis of acyl-coenzyme A 
(CoA) to the free fatty acid and coenzyme A, regulating intracellular levels of acyl-CoA and 
fatty acids. Selected fatty acids are associated with adverse outcomes including 
dyslipidemia, inflammation, myocardial infarction, and other cardiovascular mortality.32–36 
Human ACOT4 hydrolyzes succinyl-CoA, glutaryl-CoA, and long-chain acyl-CoA reactions 
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catalyzed by multiple enzymes in other species. Expression of ACOT4 is regulated by 
peroxisome proliferator-activated receptor-α,37,38 a nuclear receptor that has been 
implicated in vascular and cardiac disease and represents a therapeutic target in diabetes 
mellitus.39 ACOT4 links risk for ischemic stroke with fatty acid metabolism.
This study, which we believe to be the largest on exome sequencing in stroke, has 
limitations. The replication of PDE4DIP rs1778155 association with ischemic stroke 
succeeded in both affected sibpair families and a small case-control cohort of African 
ancestry; however, it was not replicated in ExomeChip analyses. Furthermore, the ACOT4 
rs35724886 infrequent variant was not informative in the replication samples and, therefore, 
was not replicated. Because these are protein-coding variants, their coverage in GWAS 
reports (eg, METASTROKE)40 is often incomplete. PDE4DIP rs1778155 has no surrogate 
within r2 value greater than 0.4 in the 1000 Genomes Project data; ACOT4 rs35724886 has 
no surrogate within r2 value greater than 0.8 in the ACOT2/ACOT4/ACOT6 cluster. In the 
joint ImmunoChip/WTCCC2/METASTROKE data,40 the PDE4DIP rs1778155 variant is 
20.5 Mb proximal to the SELP (selectin P [granule membrane protein 140kDa, antigen 
CD62; 1q24.2]; GenBank NM_003005) rs3917792 variant (intronic, associated with all 
ischemic stroke: OR, 1.14; P = 1.76 × 10−7). However, ACOT4 rs35724886 is only 1.4 Mb 
from the METASTROKE-identified RGS6 (regulator of G-protein signaling 6; 14q24.2; 
GenBank NM_001204416) rs2238238 variant (intronic, associated with all ischemic stroke: 
OR, 1.18; P = 1.65 × 10−6). Thus, METASTROKE provides indirect support for the ACOT4 
contribution to ischemic stroke. Several candidate genes and loci were not analyzed, since 
few protein-coding variants were identified through ESP exome sequencing or included on 
the ExomeChip (eg, HDAC9, PDE4D). The 9p21.3 region, previously associated with large-
vessel ischemic stroke, contains few protein-coding genes and, therefore, few coding-region 
variants. Only 3 variants in CDKN2A (cyclin-dependent kinase inhibitor 2A; GenBank 
NG_007485) and 1 variant in CDKN2B-AS1 (CDKIN2B-antisense RNA 1; GenBank 
HG975381) were analyzed, with no variant associated with overall ischemic stroke or stroke 
subtype. Finally, our discovery sample focused on small- and large-vessel ischemic stroke 
subtypes to increase statistical power to detect novel genetic loci and reduce heterogeneity. 
Subsequent epidemiologically robust sampling approaches, consistent with the underlying 
distribution of subtypes in the population, should be conducted. Such studies would enable 
estimation of risk attributable to these genes (eg, PDE4DIP and ACOT4) and pathways to 
small-and large-vessel stroke and the effect of these variants in individual risk profiles for 
ischemic stroke.
The NHLBI ESP is the first large-scale exome sequencing project to focus on complex 
human phenotypes rather than mendelian disorders. Although data from both European 
Americans and African Americans were sequenced in the ESP, only European Americans 
had sufficiently large numbers of ischemic stroke to permit robust genetic analyses. The 
motivation for exploring the exome was that the protein-coding region variants would have 
greater likelihood of functional impact and, therefore, larger effects on disease risk, although 
examples of this remain few and require large sample sizes, similar to those of GWAS. 
Nevertheless, exome sequencing has, as exhibited in the present study, provided novel gene 
targets and biological pathways for examination on their role in ischemic stroke.
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Our study has led to the identification of 2 novel genes (PDE4DIP and ACOT4) and the 
replication of 2 previously reported candidate genes (ABCA1 and ZFXH3) as containing 
coding region variants associated with ischemic stroke. These new results suggest that2 
pathways, involving cell migration and growth (PDE4DIP) and long-chain fatty acid 
metabolism (ACOT4), could provide insights into the cause of ischemic stroke and as targets 
for pharmacologic interventions and therapies.
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Table 1




Type of Stroke, No. (%)
Female, No./




EA ESP 312/365 (85.5) 62.4 (11.6) 249 (68.2) 114 (31.2) 0 2 (0.5) 460/809 (56.9) 58.5 (11.7)
AA ESP 68/83 (81.9) 57.0 (9.2) 57 (68.7) 23 (27.7) 0 3 (3.6) 215/317 (67.8) 59.3 (8.3)
SWISS 36/94 (38.3) 67.4 (11.5) 56 (59.6) 38 (40.4) 0 0 NA NA
WHI ExomeChip 1672/1672 (100) 68.7 (5.8) 224 (13.4) 107 (6.4) 605 (36.2) 736 (44.0) 4509/4509 (100) 66.9 (6.4)
Abbreviations: AA, African ancestry; EA, European ancestry; ESP, Exome Sequencing Project; NA, not available; SWISS, Siblings With Ischemic 
Stroke Study; WHI, Women's Health Initiative.
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